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ABSTRACT
Combination therapy with a b-lactam plus an aminoglycoside has been the standard approach for
treating febrile neutropenia for many years. More recently, b-lactam monotherapy has also been shown
to be a reliable and safe approach. In the present study, 763 eligible patients with fever and neutropenia
received piperacillin–tazobactam monotherapy. On day 3, according to the study protocol, 165 patients
with persistent fever who fulfilled the study entry criteria were randomised to receive vancomycin or a
placebo. The success rate was 51% in the intention-to-treat analysis and 62% in the per-protocol
analysis. The overall mortality rate was 8% (58 ⁄ 763), with only 18 (2.4%) deaths attributed to the initial
or subsequent infection. Randomisation had no influence on the study endpoints. The adverse event rate
was evaluated only in the patient population not included in the randomised part of the study. Among
these patients, adverse events probably or definitely related to piperacillin–tazobactam therapy were
uncommon, confirming the favourable safety profile of piperacillin–tazobactam. It was concluded that
piperacillin–tazobactam could be considered as monotherapy for patients with high-risk febrile
neutropenia.
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INTRODUCTION
Infection remains an important cause of morbid-
ity and mortality in patients with cancer, parti-
cularly those receiving anti-neoplastic therapy for
haematological malignancies. Several studies
have been performed with the aim of determining
the most effective antibiotic regimen in these
patients, but there remain issues that must be
resolved on a case-by-case basis [1]. Risk-adapted
strategies are being introduced following the
identification of categories of low-risk patients
[2], and it is now clear that some patients can be
treated safely with oral therapy [3,4]. However,
intravenous therapy remains the treatment of
choice for high-risk patients, despite disagree-
ment between advocates of combination therapy
and those of monotherapy. There is also contro-
versy regarding the treatment of persistently
febrile patients, with some haematological centres
adding vancomycin on an empirical basis after
2–3 days of antibiotic therapy.
With the dual aims of testing the efficacy
of piperacillin–tazobactam as monotherapy in
empirical treatment of febrile neutropenia, and
evaluating whether the empirical addition of
vancomycin was associated with a better out-
come, the International Therapy Group of the
European Organization for Research and Treat-
ment of Cancer (EORTC-IATG) performed a
clinical trial in which febrile and neutropenic
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patients were treated initially with piperacillin–
tazobactam monotherapy in the setting of a
non-comparative study. Persistently febrile neu-
tropenic patients with fever of unknown origin,
clinically documented infection, or bacteraemia
caused by piperacillin–tazobactam-susceptible
microorganims, were then randomised to receive
either vancomycin or a placebo. The methodology
and results of the vancomycin vs. placebo part of
the study (165 patients) have been published
elsewhere [5]. The present report describes the
total study population (763 patients). For the
purpose of the present analysis, patients who
entered the randomised part of the study were
evaluated along with all other patients for
response to piperacillin–tazobactam, since the
previous study showed that the empirical addi-
tion of vancomycin had the same effect as placebo
and therefore had no influence on the final
outcome [5].
MATERIALS AND METHODS
Thirty-four centres in Europe, the Middle East and North
America participated in the study. Definitions of febrile
episodes, clinical assessments, further infections and toxicity,
as well as microbiological methods, were as described previ-
ously [6]. Death was attributed to infection when it occurred as
a direct consequence of either the presenting infection or a
further infection. All case reports were reviewed by the Data
Review Committee for completeness, accuracy, eligibility
criteria and assessment of the outcome variables. The Data
Review Committee classified a patient’s trial as non-evaluable
if a protocol violation precluded evaluation of the patient’s
response. The study was approved by the Protocol Review
Committee of the EORTC and by the Ethical Committee of
each participating institution. Piperacillin–tazobactam was
given intravenously at a dose of 4 g ⁄ 500 mg every 6 h in
adults and in children weighing > 50 kg (80 mg ⁄ 10 mg ⁄ kg
body weight every 6 h in children £ 50 kg), until success or
failure (see below). The minimum duration of treatment was
7 days, with at least 4 days without fever.
Eligibility criteria
Eligible patients were febrile and granulocytopenic, with a
diagnosis of leukaemia, lymphoma or Hodgkin’s disease, or
who were undergoing stem-cell or bone marrow transplanta-
tion for a neoplastic disease. Granulocytopenia was defined as
an absolute granulocyte count of < 1000 cells ⁄mm3, expected
to fall to < 500 cells ⁄mm3 within 24–48 h, and to last for
> 7 days (from the onset of fever). Fever was defined as the
presence of an oral or axillary temperature ‡ 38.5C in a single
measurement, or ‡ 38C on two or more occasions separated
by at least 1 h during a 12-h period. Exclusion criteria were an
obvious non-infectious cause of fever, age < 2 years, treatment
with any intravenous antibacterial agent in the 4-day period
preceding the study, known allergy to any of the antibiotics
used in the study, previous inclusion in the study, renal failure
(requiring haemodialysis or peritoneal dialysis, or serum
creatinine > 200 lmol ⁄L or > 2.25 mg ⁄dL, or an estimated
creatinine clearance of < 40 mL ⁄min in adult patients), high
probability of death within 48 h, catheter-related infection,
lung infiltrate, pregnancy, or known infection with human
immunodeficiency virus. Written informed consent was
required, and enrolment details were centralised at the
EORTC-IATG Data Centre.
Study endpoints and analysis
Both intention-to-treat (ITT) and per-protocol (PP) analyses
were performed. Success was defined as resolution of fever
and clinical signs of infection (where present) for four
consecutive days, no relapse within 1 week of discontinuing
therapy, and eradication of the infecting microorganisms
(when isolated) without modification of treatment. Enrolment
in the randomised part of the study was not considered to be a
change of treatment, since it was not associated with any
difference in the outcome. Failure was defined as one of the
following events: death resulting from infection, persistence of
bacteraemia, shock, acute respiratory distress syndrome, dis-
seminated intravascular coagulation or multiple organ failure
attributable to infection after exclusion of other causes,
breakthrough bacteraemia, or relapse of the primary infection
within 7 days of discontinuing therapy. Patients with micro-
biologically documented viral, fungal or mixed infections, or
with microbiologically documented bacterial infections caused
by an organism resistant to piperacillin–tazobactam (defined
for methicillin-susceptible staphylococci as an MIC
‡ 16 ⁄ 4 mg ⁄L, and for all other bacteria as either an inhibition
zone diameter £ 17 mm or an MIC > 128 ⁄ 4 mg ⁄L), were also
categorised as treatment failures, regardless of the clinical
course. Excluding patients randomised for vancomycin or
placebo, the addition of any antibiotic to piperacillin–tazobac-
tam was considered to be a treatment failure. However, the
protocol allowed the addition of an aminoglycoside for
patients with Gram-negative bacteraemia, as soon as blood
cultures were reported positive for a Gram-negative bacillus,
pending in-vitro susceptibility results. Thus, some patients in
the piperacillin–tazobactam monotherapy arm received addi-
tional amikacin therapy following documentation of Gram-
negative bacteraemia. These patients were included in the
analysis, but were considered to represent treatment failures in
the ITT analysis, and were excluded from the PP analysis.
RESULTS AND DISCUSSION
In total, 859 febrile neutropenic cancer patients
received piperacillin–tazobactam monotherapy.
Of these, 96 were ineligible because of an expec-
ted short duration of neutropenia or no neutrope-
nia (n = 65), an unconfirmed diagnosis of cancer
(n = 10), no confirmed fever (n = 6), previous
inclusion in the trial (n = 5), presence of a lung
infiltrate (n = 5), and other reasons (n = 5). As
shown in Table 1, acute leukaemia was the
predominant underlying disease (62%), and the
mean duration of neutropenia was 17.5 days
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(range 3–84 days). Febrile episodes were associ-
ated with bacteraemia in 218 (29%) patients
(Gram-negative bacteria, n = 92; Gram-positive
bacteria, n = 97; polybacterial, n = 29), with
microbiologically documented infection without
bacteraemia in 25 (3%) patients, clinically docu-
mented infection in 92 (12%) patients, and fever
of unknown origin in 416 (55%) patients. Seven
patients (1%) had fever that was unrelated to
infection, three had fungal infections and two had
viral infections.
All 763 eligible patients were included in the
ITT analysis. Patients included in the randomised
part of the study were evaluated clinically with all
other patients. As shown in Table 2, 388 (51%) of
763 patients were treated successfully according
to the above definitions. Among the treatment
failures, 23 patients with Gram-negative bacter-
aemia received an aminoglycoside pending the
results of susceptibility tests. Only three of the
corresponding 26 isolates were found subse-
quently to be resistant to piperacillin–tazobactam
in vitro.
After exclusion of patients because of treat-
ment modification without adequate reason
(n = 84), addition of an aminoglycoside within
the first 60 h (n = 23), therapy for an inadequate
period (n = 16), fever unrelated to infection
(n = 7), and other conditions (n = 24), the PP
analysis was conducted with 609 patients. With-
in the PP group, the response rate was 62%
(377 ⁄ 609). Reasons for treatment failure inclu-
ded persistent fever (n = 28), documented clin-
ical deterioration (n = 119), isolation of a
resistant bacterial pathogen (n = 32), break-
through bacteraemia (n = 26), development of
shock, acute respiratory distress syndrome or
multiple organ failure (n = 13), death caused by
infection (n = 3), and other reasons (n = 11). In
the subgroup of patients with bacteraemia, the
response rates were 34% and 47% in the ITT
and PP analyses, respectively. Response
rates among patients with Gram-negative,
Gram-positive and polymicrobial bacteraemias
were 34%, 38% and 21% in the ITT analysis,
and 49%, 50% and 27% in the PP analysis,
respectively. Response rates by type of micro-
organism in the PP analysis are shown in
Table 3. The response rates varied by type of
organism, but were relatively low in the sub-
groups of patients with Escherichia coli and
Pseudomonas aeruginosa bacteraemia, although
this was not caused by in-vitro resistance.
Among the 16 patients with E. coli bacteraemia
who were classified as treatment failures, in-
vitro resistance was the cause of treatment
failure in only two cases, both from the same
centre. In the other cases, reasons for treatment
failure included clinical deterioration (seven
cases), development of sepsis-related complica-
tions (six cases) and breakthrough bacteraemia
Table 1. Characteristics of patients who initially received
piperacillin–tazobactam monotherapy
Characteristic n (range or %)
Total number of patients 763
Adults 725
Children 38
Age (median) (years) 45 (2–86)
Underlying cancer
Acute leukaemia 471 (62)
Hodgkin’s disease 206 (27)
Chronic leukaemia (blast crisis) 40 (5)
Other 46 (6)
Mean duration of neutropenia (days) 17.5 (3–84)
Oral antibacterial prophylaxis 332 (44)
Quinolones 253 (33)
Co-trimoxazole 49 (6)
Oral antifungal prophylaxis 369 (48)
Oral antiviral prophylaxis 194 (25)
Table 2. Response to piperacillin–tazobactam treatment
(intention-to-treat and per-protocol analyses)
Intention-to-treat analysis
(%; 95% CI)
Per-protocol analysis
(%; 95% CI)
Overall response 388 ⁄ 763 (51; 47–54) 377 ⁄ 609 (62; 58–66)
Bacteraemia 74 ⁄ 218 (34; 28–40) 73 ⁄ 157 (47; 39–54)
Gram-negative 31 ⁄ 92 (34) 30 ⁄ 61 (49)
Gram-positive 37 ⁄ 97 (38) 37 ⁄ 74 (50)
Polymicrobial 6 ⁄ 29 (21) 6 ⁄ 22 (27; 9–46)
MDI without bacteraemia 11 ⁄ 25 (44; 24–63) 10 ⁄ 21 (52; 31–74)
Clinically documented infection 39 ⁄ 92 (42; 32–52) 39 ⁄ 74 (53; 41–64)
Fever of unknown origin 257 ⁄ 416 (62; 57–66) 254 ⁄ 354 (72; 67–76)
Fever not related to infection 7 ⁄ 7 –
Viral or fungal infection 0 ⁄ 5 0 ⁄ 3
MDI, microbiologically documented infection.
Table 3. Response to piperacillin-tazobactam treatment in
documented bacteraemias (per-protocol analysis)
Category of bacteraemia n (%)
Gram-negative bacteraemia 30 ⁄ 61 (49)
Escherichia coli 11 ⁄ 27 (41)
Klebsiella spp. 9 ⁄ 13 (69)
Enterobacter spp. 4 ⁄ 5 (80)
Pseudomonas aeruginosa 1 ⁄ 8 (13)
Other 5 ⁄ 8 (63)
Gram-positive bacteraemia 37 ⁄ 72 (51)
Methicillin-sensitive CoNS 8 ⁄ 22 (36)
Methicillin-resistant CoNS 0 ⁄ 4 (0)
Staphylococcus aureus 2 ⁄ 9 (22)
Streptococci 26 ⁄ 36 (72)
Other 1 ⁄ 1 (100)
CoNS, coagulase-negative staphylococci.
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(one case). In the seven patients with P. aerugi-
nosa bacteraemia for whom treatment failed, two
failures were caused by in-vitro resistance, and
five cases showed clinical deterioration. In all
these patients, failure was detected shortly after
the start of treatment, mainly because of haemo-
dynamic instability, but in no instance was
persistence of bacteraemia the cause of treat-
ment failure.
Overall, 58 (8%) of 763 patients died within
1 month of randomisation. Death was related to
the presenting or subsequent infection in 18
(2.4%) patients, to extensive cancer in 15 (2%)
patients, to haemorrhage in 14 (1.8%) patients,
and to other causes in nine (1.2%) patients.
Adverse events were reported only for
patients who did not enter the separate vanco-
mycin ⁄placebo study. Overall, adverse events
were recorded for 47% (281 ⁄ 598) of the patients,
with a total of 468 events. Of these, only 24 (5%)
cases were considered to be definitely or probably
related to piperacillin–tazobactam therapy. These
included rash (13 cases), diarrhoea (six), oral
candidiasis (two), vaginal candidiasis (two),
hypokalaemia (one), and jaundice (one).
Piperacillin–tazobactam has been used previ-
ously as monotherapy for the treatment of
febrile neutropenia, although mainly in low-risk
patients. In high-risk patients, piperacillin–tazo-
bactam has been used mainly in combination
with other drugs [6–10]. In the present study,
piperacillin–tazobactam performed well when
used as monotherapy in high-risk patients. The
results were in essential agreement with those
reported by Del Favero et al. [11], although Del
Favero et al. compared piperacillin–tazobactam
plus placebo with piperacillin–tazobactam plus
amikacin in a multicentre, prospective, random-
ised, double-blind clinical trial. The response
rates in the overall population were 51% in the
present study, compared to 49% in the study of
Del Favero et al. [11]. In patients with microbi-
ologically documented infections, clinically
documented infections and unexplained fevers,
response rates in the present study were 35%,
42% and 62%, respectively, compared with
32%, 54% and 62%, respectively, in the study
of Del Favero et al. [11].
Compared with a previous study [10], an
increase in the incidence of bacteraemia as a
cause of febrile episodes in neutropenia was
recorded, with the emergence of Gram-negative
bacteria (49% of single-organism bacteraemias).
This epidemiological change could be related to
reduced use of fluoroquinolone prophylaxis;
indeed, only 33% of enrolled neutropenic
patients in this study received fluoroquinolone
prophylaxis, compared with 55% in previous
trials [10,12,13]. This was anticipated in the
design of the study, so that, in order to avoid
protocol violations, the addition of an amino-
glycoside was allowed in patients with Gram-
negative bacteraemia, pending susceptibility
tests. However, the results indicated that this
precaution was not justified by the in-vitro
susceptibility data. An aminoglycoside was
added to piperacillin–tazobactam monotherapy
for 23 of 92 patients with Gram-negative bact-
eraemias, but only three of these 23 bacterial
isolates were actually resistant to piperacillin–
tazobactam. Response rates were relatively low
among patients with E. coli and P. aeruginosa
bacteraemia, which represented only 5% and
1%, respectively, of all febrile episodes, but this
was not related to reduced susceptibility to
piperacillin–tazobactam. In total, 44 E. coli were
isolated in the ITT patient group (including
isolates from polymicrobial infections), with
84% susceptibility to piperacillin–tazobactam,
and MIC50 and MIC90 values of 4 and
1024 mg ⁄L (range 1–2048 mg ⁄L), respectively.
Susceptibility to piperacillin–tazobactam was
80% for the ten P. aeruginosa isolates, with
MIC50 and MIC90 values of 16 and 512 mg ⁄L
(range: 4–1024 mg ⁄L), respectively.
In conclusion, the accumulated data indicate
that piperacillin–tazobactam should be included
in the restricted group of broad-spectrum anti-
biotics suitable for use as monotherapy for high-
risk febrile neutropenia in cancer patients,
together with carbapenems, ceftazidime and
cefepime. The choice of the initial empirical
treatment in individual patients remains an
important responsibility for physicians involved
in the clinical management of cancer patients
undergoing anti-neoplastic chemotherapy. Clin-
ical presentation, risk-factors peculiar to each
patient and local epidemiological factors should
all be taken into account, and the selection of
empirical antibiotic therapy should not be
undertaken on an automatic and uncritical
basis. In addition, the emergence of strains
producing extended-spectrum b-lactamases
should be strictly monitored, as clinical and
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microbiological treatment failures are not
uncommon with such strains.
ACKNOWLEDGEMENTS
We acknowledge the following investigators who participated
in the study and provided the majority of patients: H. Akan,
O. Marchetti, B. Vandercam, M. Aoun, A. Skoutelis, L. Drgona,
A. Schaffner, P. Pichna, V. Korten, M. Akova, G. Petri-
kkos, R. Powles, D. Caballero, M. Hatziyanni, M. Van Lint,
A. Garaventa, M. Shapiro, F. Cavalli, D. Engelhard and
F. Jacobs.
REFERENCES
1. Viscoli C, Castagnola E. Planned progressive antimicrobial
therapy in neutropenic patients. Br J Haematol 1998; 102:
879–888.
2. Klastersky J, Paesmans M, Rubenstein EB et al. The Mul-
tinational Association for Supportive Care in Cancer risk
index: a multinational scoring system for identifying low-
risk febrile neutropenic cancer patients. J Clin Oncol 2000;
18: 3038–3051.
3. Freifeld A, Marchigiani D, Walsh T et al. A double-blind
comparison of empirical oral and intravenous antibiotic
therapy for low-risk febrile patients with neutropenia dur-
ing cancer chemotherapy. N Engl J Med 1999; 341: 305–311.
4. Kern WV, Cometta A, De Bock R et al. Oral versus intra-
venous empirical antimicrobial therapy for fever in patients
with granulocytopenia who are receiving cancer chemo-
therapy. International Antimicrobial Therapy Cooperative
Group of the European Organization for Research and
Treatment of Cancer. N Engl J Med 1999; 341: 312–318.
5. Cometta A, Kern WV, De Bock R et al. Vancomycin versus
placebo for treating persistent fever in patients with neu-
tropenic cancer receiving piperacillin–tazobactam mon-
therapy. Clin Infect Dis 2003; 37: 382–389.
6. Marie JP, Verkoff A, Cony-Makhoul P et al. Piperacil-
lin ⁄ tazobactam combination + amikacin versus
ceftazidime + amikacin in patients with neutropenia and
fever. An open multicenter study. Groupe d’etude des
Aplasies Febriles. Presse Med 1995; 24: 39–41.
7. Marie JP, Marjanovic Z, Vekhoff A et al. Piperacillin ⁄
tazobactam plus tobramycin versus ceftazidime plus to-
bramycin as empiric therapy for fever in severely neu-
tropenic patients. Support Care Cancer 1999; 7: 89–94.
8. Sanz MA, Lopez J, Lahuerta JJ et al. Cefepime plus
amikacin versus piperacillin–tazobactam plus amikacin
for initial antibiotic therapy in haematology patients with
febrile neutropenia: results of an open, randomized,
multicentre trial. J Antimicrob Chemother 2002; 50: 79–88.
9. Cometta A, Zinner S, de Bock R et al. Piperacillin–tazo-
bactam plus amikacin versus ceftazidime plus amikacin as
empiric therapy for fever in granulocytopenic patients
with cancer. The International Antimicrobial Therapy
Cooperative Group of the European Organization for
Research and Treatment of Cancer. Antimicrob Agents
Chemother 1995; 39: 445–452.
10. Viscoli C. Management of infection in cancer patients:
studies of the EORTC International Antimicrobial Therapy
Group (IATG). Eur J Cancer 2002; 38: S82–S87.
11. Del Favero A, Menichetti F, Martino P et al. A multicentre,
double-blind, placebo-controlled trial comparing pipera-
cillin–tazobactam with and without amikacin as empiric
therapy for febrile neutropenia. Clin Infect Dis 2001; 33:
1295–1301.
12. EORTC-IATG, National Cancer Institute of Canada Clin-
ical Trials Group. Vancomycin added to empirical com-
bination antibiotic therapy for fever in granulocytopenic
cancer patients. J Infect Dis 1991; 163: 951–958.
13. Cometta A, Calandra T, Gaya H et al. Monotherapy with
meropenem versus combination therapy with ceftazidime
plus amikacin as empiric therapy for fever in granulocy-
topenic patients with cancer. The International Antimi-
crobial Therapy Cooperative Group of the European
Organization for Research and Treatment of Cancer and
the Gruppo Italiano Malattie Ematologiche Maligne
dell’Adulto Infection Program. Antimicrob Agents Chemo-
ther 1996; 40: 1108–1115.
216 Clinical Microbiology and Infection, Volume 12 Number 3, March 2006
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12, 212–216
